open access

Vol 15, No 1 (2008)
Review articles
Published online: 2007-12-17
Submitted: 2013-01-14
Get Citation

Importance of cardiac biomarkers in risk stratification in acute pulmonary embolism

Małgorzata Mikulewicz, Jerzy Lewczuk
Cardiol J 2008;15(1):17-20.

open access

Vol 15, No 1 (2008)
Review articles
Published online: 2007-12-17
Submitted: 2013-01-14

Abstract

At present there is consent that patients with acute pulmonary embolism (APE) and hemodynamic instability have poor prognosis and benefit from thrombolytic therapy or embolectomy, whereas hemodynamically stable patients without echocardiographic signs of right ventricular overload/dysfunction (RVO) have good prognosis and should be treated with anticoagulation alone. The optimal treatment for stable APE patients with RVO remains a challenge, and cardiac biomarkers can probably add to risk stratification and therapeutic decision making.
Troponins are indicators of irreversible cardiac cell injury, and in patients with APE even a moderate rise of the blood troponin level correlates with RVO, hemodynamic instability and cardiogenic shock. However, the positive predictive value of cardiac troponins is relatively low. It can be increased when the results of troponins and echocardiography are combined. The clinical benefits of cardiac troponins result foremost from the high negative predictive value of in-hospital events, including death. Likewise, elevated levels of natriuretic peptides such as BNP and NT-proBNP, caused by increased right ventricular stress, show close association with RVO and with increased in-hospital risk. Instead, the low level of natriuretic biomarkers indicates an uncomplicated outcome of APE.
There are some proposals of algorithms that combine both biomarkers and echocardiography for risk stratification. The principal aim of ongoing studies is to find patients with hemodynamically stable APE who can be candidates for thrombolytic therapy. The usefulness of biomarkers in long-term prognosis and their value to identify APE patients in whom chronic thromboembolic pulmonary hypertension can develop should also be confirmed. (Cardiol J 2008; 15: 17-20)

Abstract

At present there is consent that patients with acute pulmonary embolism (APE) and hemodynamic instability have poor prognosis and benefit from thrombolytic therapy or embolectomy, whereas hemodynamically stable patients without echocardiographic signs of right ventricular overload/dysfunction (RVO) have good prognosis and should be treated with anticoagulation alone. The optimal treatment for stable APE patients with RVO remains a challenge, and cardiac biomarkers can probably add to risk stratification and therapeutic decision making.
Troponins are indicators of irreversible cardiac cell injury, and in patients with APE even a moderate rise of the blood troponin level correlates with RVO, hemodynamic instability and cardiogenic shock. However, the positive predictive value of cardiac troponins is relatively low. It can be increased when the results of troponins and echocardiography are combined. The clinical benefits of cardiac troponins result foremost from the high negative predictive value of in-hospital events, including death. Likewise, elevated levels of natriuretic peptides such as BNP and NT-proBNP, caused by increased right ventricular stress, show close association with RVO and with increased in-hospital risk. Instead, the low level of natriuretic biomarkers indicates an uncomplicated outcome of APE.
There are some proposals of algorithms that combine both biomarkers and echocardiography for risk stratification. The principal aim of ongoing studies is to find patients with hemodynamically stable APE who can be candidates for thrombolytic therapy. The usefulness of biomarkers in long-term prognosis and their value to identify APE patients in whom chronic thromboembolic pulmonary hypertension can develop should also be confirmed. (Cardiol J 2008; 15: 17-20)
Get Citation

Keywords

cardiac biomarkers; acute pulmonary embolism; risk stratification

About this article
Title

Importance of cardiac biomarkers in risk stratification in acute pulmonary embolism

Journal

Cardiology Journal

Issue

Vol 15, No 1 (2008)

Pages

17-20

Published online

2007-12-17

Bibliographic record

Cardiol J 2008;15(1):17-20.

Keywords

cardiac biomarkers
acute pulmonary embolism
risk stratification

Authors

Małgorzata Mikulewicz
Jerzy Lewczuk

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl